Validation of the Achalasia Patient-Reported Outcomes Questionnaire.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
18
08
2022
received:
26
07
2022
accepted:
09
09
2022
pubmed:
21
9
2022
medline:
26
10
2022
entrez:
20
9
2022
Statut:
ppublish
Résumé
Achalasia is a debilitating major motor disorder of the oesophagus. Hypervigilance and symptom-specific anxiety substantially impact dysphagia symptom reporting, and quality of life is a critical patient outcome. Earlier achalasia symptom scales did not consider these constructs in their psychometric development. To develop a new symptom measure, the Achalasia Patient-Reported Outcomes (APRO) Questionnaire METHODS: Four gastroenterologists with achalasia expertise generated preliminary items. Patients reviewed items via cognitive interviews. Patients undergoing high-resolution manometry completed the APRO with Oesophageal Hypervigilance and Anxiety Scale, Northwestern Oesophageal Quality of Life Scale, and three measures of reflux and dysphagia. Full APRO psychometric assessment (reliability, validity, factor structure) was done. Cluster analysis evaluated APRO + symptom-anxiety/hypervigilance patient phenotypes. We included 961 patients with normal motility and 296 with achalasia. The APRO yielded three subscales: dysphagia, reflux, chest pain with two items for weight change and diet modifications. Reliability and validity were excellent. Twenty-five percent of achalasia patients may have high levels of anxiety/hypervigilance despite low symptoms, while 8% may report severe symptoms with low anxiety/hypervigilance. The APRO significantly predicted quality of life, but less cognitive-affective processes. The APRO is a reliable and valid measure of achalasia symptoms that addresses the limitations of existing questionnaires. Symptom anxiety and hypervigilance moderate the relationship between APRO and quality of life; 33% of patients with achalasia exhibit concerning patterns in symptom severity, anxiety and hypervigilance that may contribute to poorer outcomes.
Sections du résumé
BACKGROUND
Achalasia is a debilitating major motor disorder of the oesophagus. Hypervigilance and symptom-specific anxiety substantially impact dysphagia symptom reporting, and quality of life is a critical patient outcome. Earlier achalasia symptom scales did not consider these constructs in their psychometric development.
AIM
To develop a new symptom measure, the Achalasia Patient-Reported Outcomes (APRO) Questionnaire METHODS: Four gastroenterologists with achalasia expertise generated preliminary items. Patients reviewed items via cognitive interviews. Patients undergoing high-resolution manometry completed the APRO with Oesophageal Hypervigilance and Anxiety Scale, Northwestern Oesophageal Quality of Life Scale, and three measures of reflux and dysphagia. Full APRO psychometric assessment (reliability, validity, factor structure) was done. Cluster analysis evaluated APRO + symptom-anxiety/hypervigilance patient phenotypes.
RESULTS
We included 961 patients with normal motility and 296 with achalasia. The APRO yielded three subscales: dysphagia, reflux, chest pain with two items for weight change and diet modifications. Reliability and validity were excellent. Twenty-five percent of achalasia patients may have high levels of anxiety/hypervigilance despite low symptoms, while 8% may report severe symptoms with low anxiety/hypervigilance. The APRO significantly predicted quality of life, but less cognitive-affective processes.
CONCLUSIONS
The APRO is a reliable and valid measure of achalasia symptoms that addresses the limitations of existing questionnaires. Symptom anxiety and hypervigilance moderate the relationship between APRO and quality of life; 33% of patients with achalasia exhibit concerning patterns in symptom severity, anxiety and hypervigilance that may contribute to poorer outcomes.
Identifiants
pubmed: 36127750
doi: 10.1111/apt.17230
pmc: PMC9826373
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1434-1443Subventions
Organisme : NIDDK NIH HHS
ID : P01 DK117824
Pays : United States
Informations de copyright
© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
Neurogastroenterol Motil. 2015 Feb;27(2):160-74
pubmed: 25469569
Ann Thorac Cardiovasc Surg. 2020 Jun 20;26(3):113-124
pubmed: 32132346
Aliment Pharmacol Ther. 2018 May;47(9):1270-1277
pubmed: 29528128
Neurogastroenterol Motil. 2021 Oct;33(10):e14118
pubmed: 33720448
Neurogastroenterol Motil. 2021 Jan;33(1):e14058
pubmed: 33373111
Aliment Pharmacol Ther. 2021 Oct;54(7):923-930
pubmed: 34383968
Neurogastroenterol Motil. 2010 Dec;22(12):1292-7, e336-7
pubmed: 20718946
Am J Gastroenterol. 2018 Mar;113(3):348-357
pubmed: 29336433
Am J Gastroenterol. 2014 Nov;109(11):1804-14
pubmed: 25199473
Neurogastroenterol Motil. 2016 Dec;28(12):1854-1860
pubmed: 27380834
Neurogastroenterol Motil. 2021 Aug;33(8):e14081
pubmed: 33432708
Am J Gastroenterol. 2001 Jan;96(1):52-7
pubmed: 11197287
Gastroenterology. 2014 Dec;147(6):1255-66.e21
pubmed: 25160980
Gastrointest Endosc Clin N Am. 2018 Jan;28(1):35-45
pubmed: 29129298
Clin Psychol Rev. 2020 Nov;81:101894
pubmed: 32818687
Am J Gastroenterol. 2016 Apr;111(4):493-9
pubmed: 26881974
JAMA. 2015 May 12;313(18):1841-52
pubmed: 25965233
Am J Gastroenterol. 2020 Mar;115(3):367-375
pubmed: 31990697
Curr Gastroenterol Rep. 2021 Dec 1;23(12):29
pubmed: 34850300
Aliment Pharmacol Ther. 2022 Nov;56(10):1434-1443
pubmed: 36127750
Dis Esophagus. 2021 Feb 10;34(2):
pubmed: 32875315
Neurogastroenterol Motil. 2021 Sep;33(9):e14102
pubmed: 33580617
Gastroenterology. 1992 Dec;103(6):1732-8
pubmed: 1451966
Neurogastroenterol Motil. 2018 Jun;30(6):e13287
pubmed: 29315993
Soc Sci Med. 1997 Jul;45(2):221-30
pubmed: 9225410
Qual Life Res. 1993 Dec;2(6):441-9
pubmed: 8161978
Dig Dis Sci. 2018 May;63(5):1243-1249
pubmed: 29468378
Gastroenterology. 2021 Oct;161(4):1133-1144
pubmed: 34153298